Intraoperative Molecular Imaging of Lung Cancer

Lye-Yeng Wong1, Natalie S Lui2

  • 1Department of Cardiothoracic Surgery, Stanford University School of Medicine, 300 Pasteur Drive, Falk Building, Stanford, CA 94305, USA. Electronic address: https://twitter.com/LyeYengWongMD.

PubMed

Insights

New fluorescent contrast agents and camera systems are improving intraoperative molecular imaging. OTL38, a targeted near-infrared agent, is now FDA-approved for lung cancer imaging.

Area of Science:

  • Oncology
  • Medical Imaging
  • Molecular Biology

Background:

  • Intraoperative molecular imaging relies on fluorescent contrast agents and advanced camera systems.
  • Targeted agents enhance visualization of tumor tissues during surgery.

Purpose of the Study:

  • To highlight advancements in intraoperative molecular imaging.
  • To introduce OTL38 as a key innovation in this field.

Main Methods:

  • Development of fluorescent contrast agents targeting tumor tissues.
  • Utilizing advanced camera systems for fluorescence detection.

Main Results:

  • OTL38, a targeted near-infrared agent, shows significant promise.
  • OTL38 has received FDA approval for intraoperative lung cancer imaging.

Conclusions:

  • Innovations in fluorescent agents and imaging technology are transforming surgical procedures.
  • OTL38 represents a significant step forward in targeted intraoperative imaging for lung cancer.